METHOD OF TREATING AUTISM

George Lambert (Inventor), Bernd Spur (Inventor), Thomas Stein (Inventor), Sue Ming (Inventor), Ana Rodriguez-Rosich (Inventor)

Research output: Innovation

Abstract

Invention Summary:

DHA is the major brain lipid. Recent studies by several groups of investigators have shown that DHA is the parent molecule for a large number of intracellular and extracellular messengers. Chronic perturbation of the pathways regulated by these molecules could account for the subtle behavioral effects seen with neurological diseases. Oxidation of DHA gives rise to a series of non-enzymatically produced analogs of the enzymatically derived products (neuroprostanes). Since the structure and chemistries of these neuroprostanes are so similar to the enzymatically-produced compounds, interference in the signal transduction pathways is likely. If the events occur in the brain, one likely outcome is behavioral changes.

This invention relates to the identification and treatment of the effects of oxidative stress in a patient. There are three possible reasons for altered AA and or DHA metabolism: (1)The high isoprostanes reflect an overall increase in oxidative stress, (2) there is a genetic abnormality in the processing of AA and DHA and (3) pollutants trigger an abnormal response in the one or more of the AA or DHA pathways leading to isoprostanes (AA) or neuroprostanes (DHA) or resolvins (DHA) in the genetically susceptible. Whatever the pathway the result is an anomalous patterns of intracellular communication within the brain.

Market Applications:
  • Diagnosis of oxidative stress related disorders including autism. asthma, neuro-developmental disorders, inflammatory bowel disorder, Parkinson’s disease, Alzheimer’s disease, schizophrenia, ADHD, ROP and BPD/Arthritis/periodontal disease
  • Treatment of oxidative stress related disorders
  • A method of monitoring response to treatment of an oxidative stress disorders

Advantages:

This technology demonstrates a way to identify subjects with anomalous polyunsaturated fatty acid (PUFA) metabolism. More specifically, the invention discloses a methods identifying selected subgroups of autistic children using biomarkers derived from AA (arachidonic acid) and DHA (docasahexaenoic acid), treating these disorders, and monitoring treatment.

Intellectual Property & Development Status:

Published PCT application: PCT/US2011/0237669-A1

Original languageEnglish (US)
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

Autistic Disorder
Neuroprostanes
Acids
Arachidonic Acid
Oxidative Stress
Isoprostanes
Brain
Intellectual Property
Periodontal Diseases
Therapeutics
Unsaturated Fatty Acids
Arthritis
Signal Transduction
Schizophrenia
Alzheimer Disease
Asthma
Biomarkers
Communication
Research Personnel
Lipids

Keywords

  • CNS

Cite this

Lambert, G., Spur, B., Stein, T., Ming, S., & Rodriguez-Rosich, A. (2014). METHOD OF TREATING AUTISM.
Lambert, George (Inventor) ; Spur, Bernd (Inventor) ; Stein, Thomas (Inventor) ; Ming, Sue (Inventor) ; Rodriguez-Rosich, Ana (Inventor). / METHOD OF TREATING AUTISM.
@misc{19a01a444ea547c2bb43d8881b6c3226,
title = "METHOD OF TREATING AUTISM",
abstract = "Invention Summary: DHA is the major brain lipid. Recent studies by several groups of investigators have shown that DHA is the parent molecule for a large number of intracellular and extracellular messengers. Chronic perturbation of the pathways regulated by these molecules could account for the subtle behavioral effects seen with neurological diseases. Oxidation of DHA gives rise to a series of non-enzymatically produced analogs of the enzymatically derived products (neuroprostanes). Since the structure and chemistries of these neuroprostanes are so similar to the enzymatically-produced compounds, interference in the signal transduction pathways is likely. If the events occur in the brain, one likely outcome is behavioral changes. This invention relates to the identification and treatment of the effects of oxidative stress in a patient. There are three possible reasons for altered AA and or DHA metabolism: (1)The high isoprostanes reflect an overall increase in oxidative stress, (2) there is a genetic abnormality in the processing of AA and DHA and (3) pollutants trigger an abnormal response in the one or more of the AA or DHA pathways leading to isoprostanes (AA) or neuroprostanes (DHA) or resolvins (DHA) in the genetically susceptible. Whatever the pathway the result is an anomalous patterns of intracellular communication within the brain. Market Applications: Diagnosis of oxidative stress related disorders including autism. asthma, neuro-developmental disorders, inflammatory bowel disorder, Parkinson’s disease, Alzheimer’s disease, schizophrenia, ADHD, ROP and BPD/Arthritis/periodontal disease Treatment of oxidative stress related disorders A method of monitoring response to treatment of an oxidative stress disorders Advantages: This technology demonstrates a way to identify subjects with anomalous polyunsaturated fatty acid (PUFA) metabolism. More specifically, the invention discloses a methods identifying selected subgroups of autistic children using biomarkers derived from AA (arachidonic acid) and DHA (docasahexaenoic acid), treating these disorders, and monitoring treatment. Intellectual Property & Development Status: Published PCT application: PCT/US2011/0237669-A1",
keywords = "CNS",
author = "George Lambert and Bernd Spur and Thomas Stein and Sue Ming and Ana Rodriguez-Rosich",
year = "2014",
month = "3",
language = "English (US)",
type = "Patent",

}

Lambert, G, Spur, B, Stein, T, Ming, S & Rodriguez-Rosich, A 2014, METHOD OF TREATING AUTISM.

METHOD OF TREATING AUTISM. / Lambert, George (Inventor); Spur, Bernd (Inventor); Stein, Thomas (Inventor); Ming, Sue (Inventor); Rodriguez-Rosich, Ana (Inventor).

Research output: Innovation

TY - PAT

T1 - METHOD OF TREATING AUTISM

AU - Lambert, George

AU - Spur, Bernd

AU - Stein, Thomas

AU - Ming, Sue

AU - Rodriguez-Rosich, Ana

PY - 2014/3

Y1 - 2014/3

N2 - Invention Summary: DHA is the major brain lipid. Recent studies by several groups of investigators have shown that DHA is the parent molecule for a large number of intracellular and extracellular messengers. Chronic perturbation of the pathways regulated by these molecules could account for the subtle behavioral effects seen with neurological diseases. Oxidation of DHA gives rise to a series of non-enzymatically produced analogs of the enzymatically derived products (neuroprostanes). Since the structure and chemistries of these neuroprostanes are so similar to the enzymatically-produced compounds, interference in the signal transduction pathways is likely. If the events occur in the brain, one likely outcome is behavioral changes. This invention relates to the identification and treatment of the effects of oxidative stress in a patient. There are three possible reasons for altered AA and or DHA metabolism: (1)The high isoprostanes reflect an overall increase in oxidative stress, (2) there is a genetic abnormality in the processing of AA and DHA and (3) pollutants trigger an abnormal response in the one or more of the AA or DHA pathways leading to isoprostanes (AA) or neuroprostanes (DHA) or resolvins (DHA) in the genetically susceptible. Whatever the pathway the result is an anomalous patterns of intracellular communication within the brain. Market Applications: Diagnosis of oxidative stress related disorders including autism. asthma, neuro-developmental disorders, inflammatory bowel disorder, Parkinson’s disease, Alzheimer’s disease, schizophrenia, ADHD, ROP and BPD/Arthritis/periodontal disease Treatment of oxidative stress related disorders A method of monitoring response to treatment of an oxidative stress disorders Advantages: This technology demonstrates a way to identify subjects with anomalous polyunsaturated fatty acid (PUFA) metabolism. More specifically, the invention discloses a methods identifying selected subgroups of autistic children using biomarkers derived from AA (arachidonic acid) and DHA (docasahexaenoic acid), treating these disorders, and monitoring treatment. Intellectual Property & Development Status: Published PCT application: PCT/US2011/0237669-A1

AB - Invention Summary: DHA is the major brain lipid. Recent studies by several groups of investigators have shown that DHA is the parent molecule for a large number of intracellular and extracellular messengers. Chronic perturbation of the pathways regulated by these molecules could account for the subtle behavioral effects seen with neurological diseases. Oxidation of DHA gives rise to a series of non-enzymatically produced analogs of the enzymatically derived products (neuroprostanes). Since the structure and chemistries of these neuroprostanes are so similar to the enzymatically-produced compounds, interference in the signal transduction pathways is likely. If the events occur in the brain, one likely outcome is behavioral changes. This invention relates to the identification and treatment of the effects of oxidative stress in a patient. There are three possible reasons for altered AA and or DHA metabolism: (1)The high isoprostanes reflect an overall increase in oxidative stress, (2) there is a genetic abnormality in the processing of AA and DHA and (3) pollutants trigger an abnormal response in the one or more of the AA or DHA pathways leading to isoprostanes (AA) or neuroprostanes (DHA) or resolvins (DHA) in the genetically susceptible. Whatever the pathway the result is an anomalous patterns of intracellular communication within the brain. Market Applications: Diagnosis of oxidative stress related disorders including autism. asthma, neuro-developmental disorders, inflammatory bowel disorder, Parkinson’s disease, Alzheimer’s disease, schizophrenia, ADHD, ROP and BPD/Arthritis/periodontal disease Treatment of oxidative stress related disorders A method of monitoring response to treatment of an oxidative stress disorders Advantages: This technology demonstrates a way to identify subjects with anomalous polyunsaturated fatty acid (PUFA) metabolism. More specifically, the invention discloses a methods identifying selected subgroups of autistic children using biomarkers derived from AA (arachidonic acid) and DHA (docasahexaenoic acid), treating these disorders, and monitoring treatment. Intellectual Property & Development Status: Published PCT application: PCT/US2011/0237669-A1

KW - CNS

UR - http://rutgers.technologypublisher.com/tech/METHOD_OF_TREATING_AUTISM

M3 - Innovation

ER -

Lambert G, Spur B, Stein T, Ming S, Rodriguez-Rosich A, inventors. METHOD OF TREATING AUTISM. 2014 Mar.